CF
UNCY icon

Cantor Fitzgerald’s Unicycive Therapeutics UNCY Stock Holding History

Cantor Fitzgerald’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$494K Sell
75,000
-125,000
-63% -$819K 0.01% 220
2025
Q4 		$1.15M Buy
+200,000
New +$1.07M 0.02% 156
2025
Q2 		– Sell
-3,297
Closed -$19K – 541
2025
Q1 		$19K Buy
+3,297
New +$20.1K ﹤0.01% 272

Other funds holding UNCY

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cantor Fitzgerald's UNCY Position: Q1 2026 in Review

Cantor Fitzgerald reduced its Unicycive Therapeutics (UNCY) stake by 63% in Q1 2026, selling an estimated $819K and leaving 75,000 shares worth $494K. The position accounts for 0.01% of the portfolio, ranked #220.

Cantor Fitzgerald first reported a position in UNCY in Q1 2025 and has held it in 3 quarters since. The position peaked at $1.15M in Q4 2025. 51 funds tracked by Wall St. Rank hold UNCY as of Q1 2026.

  • Cantor Fitzgerald held 75,000 shares of Unicycive Therapeutics worth $494K as of Q1 2026.
  • Cantor Fitzgerald sold 125,000 Unicycive Therapeutics shares in Q1 2026, an estimated $819K.
  • Unicycive Therapeutics made up 0.01% of Cantor Fitzgerald's portfolio in Q1 2026, its #220 holding.
  • Cantor Fitzgerald first reported a position in Unicycive Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • Cantor Fitzgerald's Unicycive Therapeutics position peaked at $1.15M in Q4 2025.
  • 51 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q1 2026.

Based on Cantor Fitzgerald's 13F filing for Q1 2026, filed 15 May 2026.